Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.92 USD | -0.76% |
|
+7.07% | -15.51% |
03:15pm | InMode Says FDA Clears Morpheus8 Technology for Soft Tissue Contraction | MT |
Jul. 15 | Barclays Lowers Price Target on InMode to $29 From $33, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.51% | 1.61B | |
+4.70% | 212B | |
+8.66% | 187B | |
+27.68% | 155B | |
+34.11% | 115B | |
+2.17% | 65.5B | |
+13.77% | 52.87B | |
-3.30% | 45.25B | |
-3.74% | 39.7B | |
+6.27% | 37.72B |
- Stock Market
- Equities
- INMD Stock
- News InMode Ltd.
- Transcript : InMode Ltd., Q2 2023 Earnings Call, Jul 27, 2023